Brain tumors and poliomavirus by Ramon Francàs, Gemma de & Universitat Autònoma de Barcelona. Facultat de Biociències
      Brain Tumors and Poliomavirus 
 Gemma de Ramon Francàs, Biochemistry Degree 
 gemma.francas@gmail.com 
Introduction 
Primary brain tumors involve the neoplastic processes arising in the Central Nervous System (CNS) structures4.. These tumors cause significant 
morbidity and mortality in both adults and children, despite its incidence is lower than in other types of cancer. Polyomaviruses are a family of non-
enveloped dsDNA viruses that infect many vertebrate species. Nowadays there is a big controversy about whether polyomavirus may have an 
important role on brain’s tumors’ origins. The aim of this project is to determine if there is an association between John Cunningham Virus (JCV), one 
member of this virus’ family, and some types of CNS tumors (Figure 1). 
Figure 1. The JCV infection occurs in 
early ages and is usually 
asymptomatic. After this primary 
infection, JCV remains in a latent 
state. Immunosupressed states can 
lead to a neuroinvasion. In the brain, 
JCV can productively infect the 
oligodendrocytes and conduce to 
Progressive Multifocal 
Leucoencephalopaty (PML), a fatal 
demyelinating disease of the CNS 
caused by the lysis of this cells. The 
virus can also remain in the brain in a 
latent way or induce a tumorigenic 
process3.. Astrocytomas, 
Medulloblastomas and Glioblastomas 
are the most common brain tumors 
related with this virus.  
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There are in vivo and ex vivo experiments in favor of the association of JCV and 
brain tumors: 
 
Cell cultures have a transformed phenotype after JCV exposure. 
Brain tumors after inoculation of JCV in experimental animals. Brain tumor 
type depends on the way of administration. 
Transgenics mice for JCV develop tumors in CNS and other types of 
cancer. The tumoral cells depend on the strand of JCV used. 
 
However, there are not epidemiologic data that supports the correlation between 
JCV and human neoplasia. JCV is an unique virus and for this reason it is too 
difficult to develop epidemiologic assays. JCV may influence some cancer types 
but is not clear in which tumors it is involved. For this reason, the debate 
remains still open. 
 
Possible Association between 
JCV and Brain Tumors 
JCV could infect the cells in early steps of tumorigenic process. Due to its 
capacity to induce genomic instability and to interact with cellular 
proteins, JCV can  perform a “Hit and run” mechanism. 
It is possible that JCV initially infects rapidly dividing tumor cells and 
expression of viral early genes then contributes to oncogenesis. If this 
type of JCV infection occurs in a cell that is already undergoing aberrant 
cell growth JCV may provide the “2nd hit” according to Knudson’s two-hit 
hypothesis of cancer development.  
High phenotype complexity of cancer makes difficult to 
determine the specific functions of infectious agents. Moreover, 
there is a long period of latency between inoculation time and 
symptom onset and environmental co-factors or host factors 
modulates the pathogenesis. 
Immune system plays a important role in the pathological 
progression.  
It’s important to develop new therapeutic agents for the possible 
new aims. There are some effective therapies based on siRNA 
against LT but it’s important to continue  the research. 
Polyomavirus as a risk factor of certain cancers: 
The most important protein in the tumorigenic process is Large T Antigen (LT) due to its interactions with multiple cellular process (Figure 2A), but 
other viral proteins are also involved (Figures 2. C-B): small T antigen (st) and Angoprotein (Agno)1.. 
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Figure 2. Schema of LT (A), Agno (B) and st (C) interactions with cellular mechanisms. 
